TY - JOUR
T1 - Optimizing a mHealth physical activity intervention with mindful awareness lessons in breast cancer survivors
T2 - Fit2ThriveMIND protocol
AU - Wolter, Melanie
AU - Reading, Jean M.
AU - Solk, Payton
AU - Starikovsky, Julia
AU - Hasanaj, Kristina
AU - Wang, Shirlene D.
AU - Siddique, Juned
AU - Horowitz, Bruriah
AU - Spring, Bonnie
AU - Carden, Lillian B.
AU - Fox, Rina
AU - Sauer, Christina
AU - Freeman, Hannah
AU - Frey, Julia
AU - Victorson, David
AU - Phillips, Siobhan M.
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/9
Y1 - 2025/9
N2 - Fit2ThriveMIND is a theory-guided moderate to vigorous physical activity (MVPA) promotion trial guided by the Multiphase Optimization Strategy (MOST) framework to evaluate the efficacy of four intervention components for increasing MVPA among inactive, post-treatment breast cancer survivors (BCS; n = 304). All participants receive a core mHealth intervention, including a Fitbit and custom-built self-monitoring Fit2ThriveMIND smartphone application. Participants are randomized to one of 16 intervention conditions, reflecting every possible combination of the four intervention components, each of which has two levels (Yes v. No): 1) Buddy, 2) E-Coach, 3) General Mindfulness (MIND), 4) MVPA-guided mindfulness (PAMIND). The primary aim is to determine the individual and combined effects of the intervention components on accelerometer-assessed MVPA at 24-weeks (post-intervention) and 48-weeks follow-up. The secondary aim is to examine how changes in MVPA influence patient-reported outcomes, other intensity activities (light and sedentary), and sleep duration and quality. All components have a 24-week duration, except E-coaching, which includes “boosters” personalized to an individual's MVPA goal attainment during weeks 25–48. Fit2ThriveMIND represents the first systematic effort to use MOST to design an optimized mHealth MVPA intervention for BCS that incorporates mindfulness and tests a maintenance strategy. This trial will improve understanding of how to effectively and efficiently change and maintain MVPA among BCS to inform more effective and scalable interventions to improve health and disease outcomes. Clinical Trials Registration #NCT05931874.
AB - Fit2ThriveMIND is a theory-guided moderate to vigorous physical activity (MVPA) promotion trial guided by the Multiphase Optimization Strategy (MOST) framework to evaluate the efficacy of four intervention components for increasing MVPA among inactive, post-treatment breast cancer survivors (BCS; n = 304). All participants receive a core mHealth intervention, including a Fitbit and custom-built self-monitoring Fit2ThriveMIND smartphone application. Participants are randomized to one of 16 intervention conditions, reflecting every possible combination of the four intervention components, each of which has two levels (Yes v. No): 1) Buddy, 2) E-Coach, 3) General Mindfulness (MIND), 4) MVPA-guided mindfulness (PAMIND). The primary aim is to determine the individual and combined effects of the intervention components on accelerometer-assessed MVPA at 24-weeks (post-intervention) and 48-weeks follow-up. The secondary aim is to examine how changes in MVPA influence patient-reported outcomes, other intensity activities (light and sedentary), and sleep duration and quality. All components have a 24-week duration, except E-coaching, which includes “boosters” personalized to an individual's MVPA goal attainment during weeks 25–48. Fit2ThriveMIND represents the first systematic effort to use MOST to design an optimized mHealth MVPA intervention for BCS that incorporates mindfulness and tests a maintenance strategy. This trial will improve understanding of how to effectively and efficiently change and maintain MVPA among BCS to inform more effective and scalable interventions to improve health and disease outcomes. Clinical Trials Registration #NCT05931874.
KW - Breast cancer survivors
KW - Mindfulness training
KW - Multiphase optimization strategy
KW - Physical activity
KW - Technology
UR - https://www.scopus.com/pages/publications/105012394336
UR - https://www.scopus.com/pages/publications/105012394336#tab=citedBy
U2 - 10.1016/j.cct.2025.108038
DO - 10.1016/j.cct.2025.108038
M3 - Article
C2 - 40752821
AN - SCOPUS:105012394336
SN - 1551-7144
VL - 156
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
M1 - 108038
ER -